Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 2,003 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Arthritis, Rheumatoid
Interventions: BI 695500; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 26 more

Conditions: Tympanomastoid Surgery, Cochlear Implant, Mastoidectomy, Cholesteatoma
Interventions: 0.25% Bupivacaine + Clonidine; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Year to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions: MRTX849, Pembrolizumab, Cetuximab, Afatinib; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 221
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 156 more

Conditions: Pain, Postoperative
Interventions: Fentanyl, Naltrexone; Drug
Lead sponsor: Incline Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Uterine Fibroids
Interventions: Telapristone acetate; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Fort Lauderdale, Florida • Atlanta, Georgia • Sandy Springs, Georgia + 4 more

Conditions: Severe Asthma
Interventions: Verekitug (UPB-101), Placebo; Drug
Lead sponsor: Upstream Bio Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 55
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 47 more

Conditions: Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions: caspofungin acetate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more

Conditions: Any Chronic, Non-traumatic Orthopedic Condition
Interventions: LLM-facilitated cognitive debiasing aid; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: ART, HIV
Interventions: Biktarvy; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obesity, Diabetes Mellitus, Type 2
Interventions: nutrition education plus active supplement, nutrition education plus inactive supplement; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 13 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Interventions: Hyperpolarized (HP) 13C, Hyperpolarized 13C-Urea, Magnetic Resonance Imaging, Saline Flush; Drug · Procedure
Lead sponsor: Michael Ohliger, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Simvastatin, Rosuvastatin, MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Human Immunodeficiency Virus, STDs, Hepatitis, Viral, Human
Interventions: Tailored Cue Cards; Behavioral
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Alcohol Dependence
Interventions: Alcohol administration; Placebo administration; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Healthy
Interventions: TMAO dietary precursors, Control (or active comparator); Other
Lead sponsor: Cornell University; Other
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Ithaca, New York

Conditions: Acute Pain, Chronic Pain, Healthy Volunteer
Interventions: Oxytocin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Choroideremia
Interventions: BIIB111; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Boston, Massachusetts • Cincinnati, Ohio + 1 more

Conditions: High Blood Pressure, Hypertension
Interventions: Team-Based Home Blood Pressure Monitoring; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5,760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions: alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neuroblastoma
Interventions: Injection of allogeneic neuroblastoma cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2016
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Urinary Incontinence
Interventions: Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Torrance, California

Conditions: Melanoma
Interventions: Single agent, adjuvant anti-PD1 therapy; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions: atrasentan; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: DTG, RPV, DTG/RPV FDC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Caspofungin Acetate in Treating Children With Fever and Neutropenia

Testing an AI Large Language Model Tool for Cognitive Debiasing in Musculoskeletal Care

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

Supplements for Controlling Resistance to Insulin

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

Computer-Assisted Tailored Cue-card Health [CATCH] Study

Biomarkers to Measure Treatment Response for Alcohol Dependence

Trimethylamine-N-oxide Production and Metabolism

Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

Team-Based Home Blood Pressure Monitoring

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)